

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 68434

Title: Non-alcoholic fatty liver disease, diabetes medications and blood pressure

Reviewer's code: 00054672 Position: Editorial Board

Academic degree: FEBG, MD, PhD

Professional title: Associate Professor

Reviewer's Country/Territory: Croatia

Author's Country/Territory: Greece

Manuscript submission date: 2021-05-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-23 11:00

Reviewer performed review: 2021-05-23 13:52

Review time: 2 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This is a Letter to the Editor regarding the work by Fu et al., previously published in the World Journal of Diabetes. It is a concise and augmentative reflection on the paper by Fu, which emphasises the major messages and critically reflects potential biases. I would recommend it for publication.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Diabetes

Manuscript NO: 68434

Title: Non-alcoholic fatty liver disease, diabetes medications and blood pressure

Reviewer's code: 03075520 Position: Peer Reviewer Academic degree: MD, MSc

Professional title: Chief Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2021-05-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-05-24 07:24

Reviewer performed review: 2021-06-17 06:01

Review time: 23 Days and 22 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Comments: New glucose-lowering agents reduce liver enzyme levels and BP. Whether this finding can be extended to NAFLD patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown. It is a letter of interest My detailed comments are as follows: 1. The analysis of the letter is resonable, 2. The language is fluent 3. The conclusion is confident. 4. The references are almost new I suggest that the letter may be considered for publication.